ATXS vs XLI
Astria Therapeutics Inc (ATXS) versus XLI (XLI) — a side-by-side from cached financials, not a winner call.
Astria Therapeutics Inc (ATXS) is a biotechnology company listed on US.
XLI (XLI) common stock.
Latest reported ATXS revenue for 2025-09-30 was $706.0K. Net income was -$98.4M. ATXS currently screens at market cap $382.1M.
XLI does not have a complete income-statement cache yet.
ATXS currently screens at market cap $382.1M. XLI currently screens at market cap $0.
Not investment advice. Open the ATXS and XLI stock pages for the full models.
Not investment advice.